164 related articles for article (PubMed ID: 17498561)
1. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
Sáez B; Martín-Subero JI; Lahortiga I; Largo C; Larrayoz MJ; Odero MD; Prosper F; Cigudosa JC; Siebert R; Calasanz MJ
Cancer Genet Cytogenet; 2007 May; 175(1):65-8. PubMed ID: 17498561
[TBL] [Abstract][Full Text] [Related]
2. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
3. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
4. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
Martin LD; Harizanova J; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2016 Dec; 55(12):962-974. PubMed ID: 27509849
[TBL] [Abstract][Full Text] [Related]
6. V. Molecular classification and risk stratification of myeloma.
Bergsagel PL; Chesi M
Hematol Oncol; 2013 Jun; 31 Suppl 1(0 1):38-41. PubMed ID: 23775647
[No Abstract] [Full Text] [Related]
7. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
8. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
9. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
[TBL] [Abstract][Full Text] [Related]
11. Comparison of IGH Profile Signals Using t(4;14) and IGH Break-Apart Probes by FISH in Multiple Myeloma.
Smol T; Daudignon A
Cytogenet Genome Res; 2017; 153(1):18-21. PubMed ID: 29040969
[TBL] [Abstract][Full Text] [Related]
12. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
[TBL] [Abstract][Full Text] [Related]
13. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell myeloma.
Lin P
Hematol Oncol Clin North Am; 2009 Aug; 23(4):709-27. PubMed ID: 19577166
[TBL] [Abstract][Full Text] [Related]
15. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
16. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.
Hudlebusch HR; Theilgaard-Mönch K; Lodahl M; Johnsen HE; Rasmussen T
Br J Haematol; 2005 Sep; 130(5):700-8. PubMed ID: 16115125
[TBL] [Abstract][Full Text] [Related]
17. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract][Full Text] [Related]
18. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
[TBL] [Abstract][Full Text] [Related]
19. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
[No Abstract] [Full Text] [Related]
[Next] [New Search]